📌 Key Takeaways
- Topic: What Is Hydrophilic Silica? Properties, Grades and Applications
- Keywords: is silicon dioxide safe
- Published: 2026-11-20 11:48:38
- Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals
Silica Powder Malaysia: Suppliers, Grades and Sourcing Options
- Calcium Carbonate Filler vs Silica: Performance, Cost and Applications Compared
- Electronic Grade Silica: Purity Requirements, Specifications and Applications
- Clinical trials involving mesoporous silica have been ongoing since 2007, discussing its potential in diverse biomedical applications (Table 3 ). To date, the clinical trials have revealed the safety and good tolerability of silica in human subjects. In 2014, MSNs as oral delivery carriers for boosting the pharmacokinetic profile of drugs with limited aqueous solubility were reported. 500 A silica NPs-lipid hybrid formulation loading with ibuprofen (Lipoceramic-IBU) was prepared. The randomized, double-blind, single-dose oral administration study (20 mg ibuprofen) was conducted on 16 healthy male volunteers. The bioavailability of Lipoceramic-IBU was found to be 1.95 times higher than that of the commercial tablet Nurofen. 500 This result suggested the secure and effective use of silica-based NPs in mimicking food impacts to optimize the oral absorption of drugs with poor water solubility. In another clinical trial consisting of 12 participants in 2016, the bioavailability of ordered MSNs-based fenofibrate formulation raised by 54.1% after a single oral dose, when compared to the commercial formulation Lipanthyl. 39 Owing to the potentially perfect clinical outcomes of silica-based nanocarriers, the pharmacokinetics, safety, and metabolic profile of a hybrid core-shell silica NP (named Cornell dots, C dots) with a diameter of 6 nm functionalized with 124 I, targeting peptide cyclo-(Arg-Gly-Asp-Tyr), and Cy5 ( 124 I-cRGDY-PEG-C' dots) is first conducted in humans utilizing PET imaging and clinical tracer at clinical trials in 2014 (NCT01266096). 58 Results showed the good safety and reproducible PK signatures of C dots with the whole-body clearance half-time of 13-21 h after intravenous administration in patients, which is shorter than 111 In labeled liposomes and 131 I-labeled humanized monoclonal antibody A33. These findings verified the possibility of these NPs for cancer diagnostics in humans. 58 Similarly, 8 nm core-shell silica NPs encapsulated with Cy5.5 in the core and connected with cRGDY on the surface (cRGDY-PEG-Cy5.5-nanoparticles) were used in patients at nanomole doses for sentinel lymph nodes detection of head and neck melanoma at a phase 1/2 human clinical trial. 501 The incredible safety, accuracy, reliability, and high contrast of these particles for visual identification of sentinel lymph nodes are irreplaceable by other available imaging molecules presently, of which phase 2 clinical trial is ongoing and will be finished in 2024 (NCT02106598). Meanwhile, another two clinical trials based on C dots are carried out. In 2018, the 89 Zr-DFO-cRGDY-PEG-Cy5-C' dots tracers were first used in both surgical and non-surgical patients for PET-CT imaging of malignant brain tumors in phase 1 clinical trial (NCT03465618). The distribution and removal profiles from the body of these particles will also be assessed till 2023. In 2019, 64 Cu-NOTA-PSMA-PEG-Cy5.5-C' dots tracer was used in another human phase 1 clinical trial for guiding the surgery of prostate cancer by PET and MRI imaging (NCT04167969).As a nanocomposite with high safety and brilliant photothermal conversion efficiency, the silica-gold NPs have also been shown to be potential therapeutic agents for plasmonic photothermal therapy of atherosclerosis (NCT01270139), 502, 503 and photothermal ablation of tumors (NCT00848042, NCT04240639). 40 In addition, an engineered mesoporous silica (SiPore15) with particle size of 1.1-1.5 μm × 0.2-0.4 μm was developed by Baek et al., and they revealed that such pure synthetic amorphous silica could remarkably decrease long-term blood glucose levels, showing good promise for the treatment of prediabetes (NCT03823027). 504 In other clinical trials, an amorphous silica-containing bioactive scaffold, called Siloss, was used to promote bone regeneration, and could be replaced by natural bone due to its fully resorbable nature (NCT02639572), and the silica-calcium phosphate nanocomposite (SCPC) was developed as graft material for the reconstruction of the volume-deficient alveolar ridges (NCT05317039). In all, these clinical trials reveal the safety and efficacy of MSNs in diverse biomedical application scenarios.
- Silica Distributor vs Manufacturer: Which Is Better for Your Purchase?
- Aluminum Silicate vs Silica: Composition, Properties and Uses Compared
- Lu, H. et al. Multi-stimuli responsive mesoporous silica-coated carbon nanoparticles for chemo-photothermal therapy of tumor. Coll. Surf. B Biointerfac. 190, 110941 (2020). Piece CAS Google Scholar
What Is Colloidal Silica? Properties, Types and Uses in Polishing, Coatings and Binders
What is silica (SiO₂)?
What is the difference between fumed silica and precipitated silica?
semiconductor grade silica
What drives silica raw material prices?
silica refractive index This review provides an overview of the development of MSNs in the biomedical field, highlighting some key research advances, briefly summarizing the types of MSNs developed by different research groups (M41S-series, SBA-series, FDU-series, KIT-series, etc.). Moreover, in view of the high versatility of MSNs-based nanocomposites for diagnostic and therapeutic applications, the current MSNs-based architectures and the types of nanocomposites by active elements are summarized. Subsequently, the purpose of surface functionalization of MSNs is examined. Further, we comprehensively review the biomedical applications of MSNs, among them biosensing, bioimaging, targeted disease therapy, and tissue engineering, etc. In particular, targeted therapeutic modalities based on various strategies are meticulously discussed. Finally, the current status of MSNs in clinical trials is presented. It is believed that this review will deliver a thorough understanding of MSNs involved in the development history, design, functionalization, and biomedical applications. In spite of numerous breakthroughs, the current challenges in MSNs research include three chief facets: systematic toxicity study, construction of straightforward but efficient MSNs-based nanoplatforms, and in-depth insight into the in vivo action mechanism.
/news/article.htmlDisclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.